Table 4.
Correlation between preoperative fibrinogen-to-albumin ratio and clinicopathological characteristics in pancreatic ductal adenocarcinoma patients who underwent R0 resection, n (%)
|
Characteristic
|
Preoperative FAR |
P
value
|
|
|
> 0.08, n = 126
|
≤ 0.08, n = 156
|
||
| Age in yr | 0.854 | ||
| > 60 | 66 (23.4) | 80 (28.4) | |
| ≤ 60 | 60 (21.3) | 76 (27.0) | |
| Sex | 0.724 | ||
| Male | 66 (23.4) | 85 (30.1) | |
| Female | 60 (21.3) | 71 (25.2) | |
| Clinical symptoms | 0.001 | ||
| Absent | 14 (5.0) | 43 (15.2) | |
| Present | 112 (39.7) | 113 (40.1) | |
| Diabetes | 0.831 | ||
| Absent | 89 (31.6) | 112 (39.7) | |
| Present | 37 (13.1) | 44 (15.6) | |
| Smoking status | 0.765 | ||
| Absent | 95 (33.7) | 120 (42.6) | |
| Present | 31 (11.0) | 36 (12.8) | |
| Alcohol consumption | 0.335 | ||
| Absent | 108 (38.3) | 127 (45.0) | |
| Present | 18 (6.4) | 29 (10.3) | |
| Family history of cancer | 0.571 | ||
| Absent | 122 (43.3) | 149 (52.8) | |
| Present | 4 (1.4) | 7 (2.5) | |
| Blood type | 0.817 | ||
| A | 36 (12.8) | 51 (18.1) | |
| B | 45 (16.0) | 48 (17.0) | |
| AB | 10 (3.5) | 12 (4.3) | |
| O | 35 (12.4) | 45 (16.0) | |
| Tumor location | < 0.001 | ||
| Head and neck | 77 (27.3) | 53 (18.8) | |
| Body and tail | 49 (17.4) | 103 (36.5) | |
| Approaches of open surgery | < 0.001 | ||
| Pancreaticoduodenectomy | 77 (27.3) | 53 (18.8) | |
| Distal pancreatectomy with splenectomy | 49 (17.4) | 103 (36.5) | |
| Degree of differentiation | 0.208 | ||
| Well | 20 (7.1) | 14 (5.0) | |
| Moderately | 93 (33.0) | 124 (44.0) | |
| Poorly | 13 (4.6) | 18 (6.4) | |
| Lymphovascular invasion | 0.729 | ||
| Absent | 92 (32.6) | 111 (39.4) | |
| Present | 34 (12.1) | 45 (16.0) | |
| Perineural invasion | 0.082 | ||
| Absent | 25 (8.9) | 45 (16.0) | |
| Present | 101 (35.8) | 111 (39.4) | |
| Capsular invasion | 0.360 | ||
| Absent | 19 (6.7) | 30 (10.6) | |
| Present | 107 (37.9) | 126 (44.7) | |
| Maximum tumor diameter in cm | 0.391 | ||
| > 4 | 36 (12.8) | 52 (18.4) | |
| ≤ 4 | 90 (31.9) | 104 (36.9) | |
| T stage | 0.462 | ||
| T1 | 13 (4.6) | 21 (7.4) | |
| T2 | 76 (27.0) | 83 (29.4) | |
| T3 | 37 (13.1) | 52 (18.4) | |
| Number of metastatic lymph nodes | 0.988 | ||
| Absent | 72 (25.5) | 89 (31.6) | |
| Present | 54 (19.1) | 67 (23.8) | |
| N stage | 0.902 | ||
| N0 | 72 (25.5) | 89 (31.6) | |
| N1 | 40 (14.2) | 52 (18.4) | |
| N2 | 14 (5.0) | 15 (5.3) | |
| TNM stage | 0.494 | ||
| IA | 6 (2.1) | 14 (5.0) | |
| IB | 40 (14.2) | 52 (18.4) | |
| IIA | 26 (9.2) | 23 (8.2) | |
| IIB | 40 (14.2) | 52 (18.4) | |
| III | 14 (5.0) | 15 (5.3) | |
| Adjuvant therapy | 0.531 | ||
| Absent | 58 (20.6) | 66 (23.4) | |
| Present | 68 (24.1) | 90 (31.9) | |
| Preoperative CA19-9 level in U/mL | 0.132 | ||
| > 336.4 | 40 (14.2) | 37 (13.1) | |
| ≤ 336.4 | 86 (30.5) | 119 (42.2) | |
| Preoperative plasma fibrinogen concentration in g/L | < 0.001 | ||
| > 3.31 | 114 (40.4) | 27 (9.6) | |
| ≤ 3.31 | 12 (4.3) | 129 (45.7) | |
| Preoperative plasma albumin level in g/L | < 0.001 | ||
| > 45.2 | 15 (5.3) | 70 (24.8) | |
| ≤ 45.2 | 111 (39.4) | 86 (30.5) | |
FAR: Fibrinogen-to-albumin ratio; TNM: Tumor-Node-Metastasis.